# Livzon Mabpharm

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/livzon-mabpharm

- Industry: Pharmaceuticals
- Headquarters: Zhuhai, China
- Website: www.livzonmabpharm.com
- Total disclosed funding: $148M
- Latest round: Series A (Jun 26, 2018)
- Investors on record: 2

## About

Livzon Mabpharm, Inc. is a biopharmaceutical company dedicated to developing and producing innovative products, particularly monoclonal antibodies, for various therapeutic areas including oncology and autoimmune disorders.Founded in 2010 in Zhuhai, China, Livzon Mabpharm, Inc. specializes in biopharmaceutical development. The company has not undergone any major pivots or changes in strategy since its inception. In June 2018, Livzon Mabpharm secured USD 148 mn in Series A funding from Livzon International Limited and YF Pharmab Limited, bringing its total funding to USD 148 mn and its current valuation to USD 548 mn.Livzon Mabpharm specializes in the development and production of innovative biopharmaceutical products, focusing primarily on monoclonal antibodies and other biologics. Their flagship offerings are designed to address a range of therapeutic areas, including oncology, autoimmune disorders, and infectious diseases. The company primarily serves hospitals, healthcare providers, and research institutions across various global markets, including Asia, Europe, and North America.Livzon Mabpharm's revenue model is structured around direct sales of its biopharmaceutical products to healthcare institutions and partnerships with distributors. The firm is known for its competitive pricing strategies that reflect the advanced technology and research invested in its flagship products. Revenue generation is further supported through strategic collaborations with pharmaceutical partners, enhancing market reach and distribution capabilities.Livzon Mabpharm plans to utilize the recently raised USD 148 mn from its Series A funding to further develop its pipeline of biopharmaceutical products. In the coming years, the company is targeting the launch of several new innovative monoclonal antibodies aimed at addressing unmet medical needs in oncology and autoimmune disorders. Additionally, Livzon Mabpharm aims to expand its market presence in Europe and North America by 2022, enhancing its distribution networks and partnerships in these critical regions.

## Funding rounds

- Series A, Jun 26, 2018, $148M — YF Capital, Livzon International Limited

## Investors

- YF Capital (https://capitalatlas.ai/funds/yf-capital) — Series A
- Livzon International Limited — Series A